Acrivastine: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: February 27, 2026🚩 Report this page

Acrivastine

Other Antihistamines For Systemic Use

Sold as BENADRYL ALLERGY RELIEF

GB MHRA

Drug class: Other Antihistamines For Systemic Use
Availability: See label
Markets covered: 1
Products on record: 4

R06AXOther Antihistamines For Systemic Use

Overview

Acrivastine is an active pharmaceutical ingredient in the Other Antihistamines For Systemic Use group (R06AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	4	February 27, 2026

GBUnited Kingdom· MHRA

4 products

Uses

GBOfficial regulatory label· revised February 28, 2025[1]

Acrivastine is indicated for symptomatic relief of allergic rhinitis, including hay fever. Acrivastine is also indicated for chronic idiopathic urticaria.

How to take

Drug interactions

Known interactions involving Acrivastine. Select one for details. This list is informational and not a complete interaction checker.

Potassium Chloride Potassium Citrate Topiramate Zonisamide Acetylcholine Aclidinium Amantadine Amitriptyline Amoxapine Apomorphine Apraclonidine Aripiprazole Asenapine Atropine Azatadine Biperiden Botulinum Toxin Type A Botulinum Toxin Type B Brexanolone Brexpiprazole Brimonidine Brompheniramine Candida Albicans Carbamoylcholine Carbinoxamine Cariprazine Chlorcyclizine Chlorpheniramine Chlorpromazine Clemastine Clidinium Clomipramine Clozapine Coccidioides Immitis Spherule Cyclizine Cyclobenzaprine Cyproheptadine Darifenacin Demecarium Desipramine Dexbrompheniramine Dicyclomine Dimenhydrinate Diphenhydramine Disopyramide Donepezil Doxepin Doxylamine Eluxadoline Esketamine Ethanol Fesoterodine Flavoxate Flibanserin Fluphenazine Galantamine Glycopyrronium Haloperidol Histamine Hydroxyzine Hyoscyamine Ifosfamide Iloperidone Imipramine Ipratropium Isocarboxazid Isoflurophate Lasmiditan Linezolid Loperamide Loxapine Lumateperone Lurasidone Maprotiline Meclizine Memantine Mepenzolate Mesoridazine Methdilazine Methotrimeprazine Methscopolamine Molindone Nortriptyline Olanzapine Olopatadine Orphenadrine Oxybutynin Paliperidone Perphenazine Phenelzine Phenindamine Phenyltoloxamine Physostigmine Pilocarpine Pimozide Pitolisant Procarbazine Prochlorperazine Procyclidine Promazine Promethazine Propantheline Propiomazine Protriptyline Pyrilamine Quetiapine Revefenacin Risperidone Rivastigmine Scopolamine Solifenacin Tacrine Thiethylperazine Thioridazine Thiothixene Tiotropium Tizanidine Tolterodine Tranylcypromine Trifluoperazine Triflupromazine Trihexyphenidyl Trimeprazine Trimipramine Tripelennamine Triprolidine Trospium Umeclidinium Ziprasidone Hyaluronidase

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL252980230 · revised February 28, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised February 28, 2025[1]

The safety of acrivastine is based on available data from 10 placebo-controlled clinical trials with a total population of 373 treated subjects, where adverse events reported by ≥1% were assessed. Additionally, adverse drug reactions (ADRs) identified during post-marketing experience are included.
The frequencies are provided according to the following convention:
Very common ≥1/10, Common ≥1/100 and < 1/10, Uncommon ≥1/1,000 and <1/100, Rare ≥1/10,000 and <1/1,000, Very rare <1/10,000, Not known (cannot be estimated from the available data). ADRs identified are presented by frequency category based on 1) incidence in adequately designed clinical trials or epidemiology studies, if available or 2) when incidence is unavailable, frequency category is listed as Not known.
Adverse Drug Reactions Identified During Post-Marketing Experience with Acrivastine Frequency Category Estimated from Clinical Trials or Epidemiology Studies SOC Frequency category Adverse Event Preferred term Immune System Disorders Not known Hypersensitivity (including Dyspnoea and face swelling) Nervous system disorders Very common Somnolence Common Dizziness Gastrointestinal Disorders Common Dry Mouth Skin and Subcutaneous Tissue Disorders Not Known Rash Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised February 28, 2025[1]

Concomitant administration of acrivastine with CNS depressants, including alcohol, sedatives, and tranquilizers, may produce additional impairment in mental alertness in some individuals. Patients with renal impairment should consult with a physician before use.
8). Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drug interactions

Drugs in the same class

Sources & citations